正海生物(300653.SZ):預計上半年淨利同比變動0%–10%
格隆匯 7 月 13日丨正海生物(300653.SZ)公佈,預計上半年實現歸屬於上市公司股東的淨利潤5,099.07萬元–5,608.98萬元,比上年同期變動:0%–10%。
受新冠肺炎疫情影響,公司2020年第一季度銷售工作受到較大影響,產品銷量明顯下降,公司通過進一步提升營銷管理水平、持續推動市場開拓和學術建設等方式保證了銷售工作的良好運行;進入第二季度,隨着國內疫情得到有效控制,公司主營業務所對應的口腔、神經外科等相關科室的手術量得到一定程度的恢復,公司二季度業績實現同比增長。
2020年上半年,公司歸屬於上市公司股東的淨利潤較去年同期穩中向好。報告期內,預計非經常性損益對歸屬於上市公司股東的淨利潤的貢獻金額為320.28萬元,非經常性損益的項目主要為收到的各類政府補助。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.